Boston Scientific Reports Q3 Profit of $582 Million
The medical device manufacturer reports its Q3 financial results as it contends with significant share price declines.
Updated on Oct. 28, 2026 in Public Companies
Live Poll
Do you trust the recent performance of large medical device manufacturers as a sign of stability?
Boston Scientific reported Q3 2026 revenue of $5.14 billion and a profit of $582 million. The company released these results in October 2026 as it navigates a challenging fiscal environment for the medical technology sector.
Why it matters
Operators monitor these figures to gauge sector-wide demand for medical devices and the impact of operational adjustments on bottom-line profitability during high-cost cycles.
Boston Scientific reported a Q3 2026 profit of $582 million on $5.14 billion in revenue. The company faces significant market pressure, with shares falling 57% over the last 12 months.
The players
Boston Scientific
A global medical technology manufacturer based in Marlborough, Massachusetts, that develops and produces devices for interventional medical specialties.
The details
The reported 40 cents per share earnings reflect net income after accounting for amortization and non-recurring expenses. The firm utilizes these adjustments to isolate core performance, guiding investors toward the 73 cents per share adjusted figure. Management currently forecasts earnings between 77 and 79 cents per share for the quarter ending in December, with full-year expectations set at $3.16 to $3.18 per share.
Timeline
Q3 2026 served as the primary reporting period for these financial results.
The financial report was published in October 2026.
The current quarter is scheduled to end in December 2026.
Market Landscape
Boston Scientific's performance highlights a disconnect between company-specific challenges and broader market trends. Its 54% year-to-date share price decline marks a significant departure from the 13% gain recorded by the S&P 500 index over the same period.
Operators in the medical supply chain should track these earnings to forecast potential procurement shifts or adjustments in device pricing. Monitoring these quarterly targets helps owners assess whether supply costs or capital constraints may disrupt near-term purchasing power.
The takeaway
Management projects full-year earnings between $3.16 and $3.18 per share, a critical benchmark for evaluating future growth capacity. Business owners should compare these forecasts against their own procurement plans to anticipate potential price adjustments in the medical device market.
What happens next
The company expects to report its next set of financial results following the close of the current quarter in December 2026.
Further reading
For more on industry benchmarks, browse our Public Companies section.
Source note: This article includes information reported by WTOP.
Live Poll
Do you trust the recent performance of large medical device manufacturers as a sign of stability?
